Fiche publication
Date publication
mai 2011
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GUILLEMIN Francis
,
Pr JOLLY Damien
,
Pr LEJEUNE Catherine
,
Pr VELTEN Michel
,
Pr WORONOFF Macha
Tous les auteurs :
Lejeune C, Loge P, Arveux P, Velten M, Jolly D, Woronoff-Lemsi MC, Guillemin F
Lien Pubmed
Résumé
BACKGROUND: Little is known about the economic burden of pretherapeutic staging of patients presenting colorectal cancer metastases. OBJECTIVE: The aim of this study was to estimate the cost of pretherapeutic staging and identify cost determinants for 132 patients presenting colorectal metastases and living in the north-east of France. METHOD: Staging cost was estimated using direct medical costs from the point of view of the French Health Insurance System. Independent factors were identified using a linear regression model, and bootstrap resampling was used to estimate unbiased standard errors and 95% confidence intervals. RESULTS: The overall mean cost for pretherapeutic staging was estimated to be 1534euro [95% CI: 1250euro-1818euro]. Staging costs increased significantly with the number of medical procedures performed during the staging, and according to health care patterns (in-patient hospital stay versus out-patient episodes, public versus private care). CONCLUSION: These results could now be used to estimate the impact of new imaging techniques on clinical practices and pretherapeutic staging costs.
Référence
Clin Res Hepatol Gastroenterol. 2011 May;35(5):399-407
